Company Filing History:
Years Active: 2016
Title: Dusan Bogunovic: Innovator in Melanoma Research
Introduction
Dusan Bogunovic is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer research, particularly in understanding metastatic melanoma. His innovative work focuses on predicting survival outcomes for patients suffering from this aggressive form of skin cancer.
Latest Patents
Dusan Bogunovic holds a patent titled "Methods for predicting survival in metastatic melanoma patients." This patent describes cellular and genetic signatures that can be used to subcategorize stage III melanoma tumors. The methods outlined in the patent are particularly useful for establishing distinct criteria to differentiate between stage IIIB and IIIC melanoma patients. By assessing the cellular and genetic signatures of melanoma samples, healthcare providers can predict differential survival duration and sensitivity to various cancer therapies for these patients. The patent emphasizes the importance of gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions to assess drug response and clinical outcomes.
Career Highlights
Dusan Bogunovic is affiliated with New York University, where he conducts his research and contributes to advancements in melanoma treatment. His work has garnered attention for its potential to improve patient outcomes through more personalized treatment approaches.
Collaborations
Dusan collaborates with notable colleagues in the field, including Nina Bhardwaj and David O'Neill. Their combined expertise enhances the research efforts aimed at understanding and combating metastatic melanoma.
Conclusion
Dusan Bogunovic's innovative contributions to melanoma research exemplify the impact of scientific inquiry on patient care. His patent and ongoing work at New York University highlight the importance of personalized medicine in oncology.